[26]

1999-2004

Hospitalized patients’ surgical and burn wounds, pus/abscess, upper respiratory tract and urine had culture obtained

1997

416 (20.8)

No genotypic characterization data reported.

Outpatients’ surgical and burn wounds, pus/abscess, upper respiratory tract and urine had culture obtained

433

35 (8.1)

No genotypic characterization data reported

[28]

2013-2014

Hospitalized patients’ clinical samples had culture obtained

294

45 (15.31)

MRSA

ST239 SCCmec III (60%)

ST8 SCCmec IV (37.78%); PVL +, “USA300”

SCCmec V (2.22%); ACME− positive

“Staphylococcus argenteus” lineages (2.38%)

MSSA

PVL− positive CC8-MSSA (20.41%) “African”

PVL− positive CC152-MSSA (9.52%)

PVL− positive CC30-MSSA (8.84%)

[29]

2016

Outpatients’ anterior nares and wound swabs had culture obtained

36

16 (44.4)

SCCmec IV (75%); PVL +

SCCmec V (25%)

[30]

2011

Hospitalized patients’ skin lesion, surgical wounds, blood and bronchial secretions had culture obtained

Data not

provided.

87

ST8 t008 SCCmec IVa (67.8%) PVL+, ACME+

ST8 t008 SCCmec IVa (13.8%) PVL+, ACME−

ST8 t008 SCCmec IVa (1.2%) PVL−, ACME−

ST8 t211 IVa (3.6%) PVL+, ACME+

ST72 t13567 SCCmec V (12.6%) PVL−, ACME−

ST72 t13567 SCCmec V (1.2%) PVL+, ACME−

[31]

2012

Hospitalized patients’ and staff’s anterior nares had cultures obtained

16

4 (25%)

t148, CC72, SCCmec IV (50%)

t002, CC5, SCCmec II (25%

t002, CC5, SCCmec IV (25%)

[32]

2017-2018

Hospitalized patients’ samples from pus, nasal cavity, wounds, catheters, blood, skin urine had cultures obtained

119

54 (45.4%)

ST8 SCCmec IV (88%) “USA300-NAE lineage”

ST5 (2.9%)

ST4080 (2.9%)

ST30-MRSA-V (1.5%)

Hospital staffs’ nasal samples had cultures obtained

33

15 (42.42%)

ST72 (1.5%)

ST121 (1.5%)

ST134 (1.5%)

[33]

2013

Hospitalized patients’ surgical wounds had culture obtained

38

15 (39.5)

No genotypic characterization reported